Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical pharmacology and therapy

• Publication date

  2009-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.2008.208PMID 19020495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

  2008cited by this paper
• Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport

  2008cited by this paper
• Uremic toxins: what are they? An integrated overview of pathobiology and classification.

  2008cited by this paper
• Prevalence of chronic kidney disease in the United States.

  2007cited by this paper
• Effects of Indoxylsulfate on the in vitro Hepatic Metabolism of Various Compounds Using Human Liver Microsomes and Hepatocytes

  2006cited by this paper
• Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis

  2006cited by this paper
• Hemodialysis acutely improves hepatic CYP3A4 metabolic activity.

  2006cited by this paper
• Effects of renal failure on drug transport and metabolism.

  2006cited by this paper
• Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450

  2005cited by this paper
• Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

  2004cited by this paper
• The Effect of Chronic Renal Failure on Hepatic Drug Metabolism and Drug Disposition

  2003cited by this paper
• Characterization of hepatic cytochrome P4503A activity in patients with end‐stage renal disease

  2003cited by this paper
• Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediators

  2002cited by this paper
• Clinical Pharmacology Studies in Patients with Renal Impairment: Past Experience and Regulatory Perspectives

  2000cited by this paper
• Decreased in vivo metabolism of drugs in chronic renal failure.

  2000cited by this paper
• Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.

  2000cited by this paper
• "Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives".

  2000cited by this paper
• Drug Administration in Patients with Renal Insufficiency

  1997cited by this paper
• Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure.

  1996cited by this paper
• The Effect of Renal Failure on Hepatic Drug Clearance

  1991cited by this paper
• Changes in erythromycin pharmacokinetics induced by renal failure.

  1987cited by this paper
• Drug metabolism and active drug metabolites in renal failure.

  1977cited by this paper

• Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study

  2026cites this paper
• Improved Prediction of Vancomycin Pharmacokinetics in Patients Receiving Continuous Renal Replacement Therapy Using a Novel Population Model Validated With Real-World Data.

  2026cites this paper
• Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib

  2025cites this paper
• Case Report: Fruquintinib-induced hyperbilirubinemia: a rare cause of dialyzer filter discoloration in a patient undergoing long-term dialysis

  2025cites this paper
• A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system

  2025cites this paper
• Intestinal transport of organic food compounds and drugs: a scoping review on the alterations observed in chronic kidney disease.

  2024cites this paper
• Chemotherapy in patients with severely reduced glomerular filtration rate: challenges and a call for improvement

  2024cites this paper
• Pharmacokinetics and Side Effects of Δ9-Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD

  2024cites this paper
• Part II: Interactive case: Critical evaluation of kidney function

  2023cites this paper
• Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

  2023cites this paper
• Pharmacokinetic relevance of glomerular hyperfiltration for drug dosing

  2023cites this paper
• Emerging Roles of Uremic Toxins and Inflammatory Cytokines in the Alteration of Hepatic Drug Disposition in Patients with Kidney Dysfunction

  2023cites this paper
• Special Section on Mechanism-Based Predictive Methods in Drug Discovery and Development — Minireview Emerging Roles of Uremic Toxins and Inflammatory Cytokines in the Alteration of Hepatic Drug Disposition in Patients with Kidney Dysfunction

  2023cites this paper
• Cancer Drug Dosing in Chronic Kidney Disease and Dialysis.

  2022cites this paper
• Interaction of Human Serum Albumin with Uremic Toxins: The Need of New Strategies Aiming at Uremic Toxins Removal

  2022cites this paper
• Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant

  2022cites this paper
• Effect of kidney disease on pharmacokinetics

  2022cites this paper
• Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment

  2022cites this paper
• Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling

  2022cites this paper
• Sources of Interindividual Variability.

  2021cites this paper
• Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment

  2021cites this paper
• Drug-drug interactions in polypharmacy patients: The impact of renal impairment

  2021cites this paper
• Design and conduct considerations for studies in patients with impaired renal function

  2021cites this paper
• Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end‐stage renal disease

  2021cites this paper
• Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy

  2021cites this paper
• High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction

  2021cites this paper
• Renal Impairment in Pediatric Patients: Current Approaches to Drug Dosing

  2021cites this paper
• Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation

  2020cites this paper
• Therapy with vitamin K antagonists in patients with atrial fibrillation and chronic kidney disease

  2020cites this paper
• Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development

  2020cites this paper
• Drug dosing in cancer patients with decreased kidney function: A practical approach.

  2020cites this paper
• Терапия антагонистами витамина К у пациентов с хронической болезнью почек и фибрилляцией предсердий

  2020cites this paper
• A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease

  2020cites this paper
• Phase I Oncology Drug Development

  2020cites this paper
• End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s

  2020cites this paper
• Clinical Pharmacology Considerations for Developing Small‐Molecule Treatments for COVID‐19

  2020cites this paper
• The Magnitude of the Warfarin‐Amiodarone Drug‐Drug Interaction Varies With Renal Function: A Propensity‐Matched Cohort Study

  2020cites this paper
• Drug Metabolism in Chronic Kidney Disease

  2020cites this paper
• Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations

  2019cites this paper
• A Randomized Clinical Trial

  2019cites this paper
• Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment

  2019cites this paper
• Physiologically‐Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection

  2019cites this paper
• COPD_A_203709 2305..2318

  2019cites this paper
• Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function

  2019cites this paper
• Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

  2019cites this paper
• Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies

  2019cites this paper
• Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End‐Stage Renal Disease on Maintenance Hemodialysis

  2019cites this paper
• Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage Schedule.

  2019cites this paper
• Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment

  2019cites this paper
• Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease

  2019cites this paper
• Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure

  2019cites this paper
• Product Labeling of Drugs Commonly Administered to Children and Adults with Obesity.

  2019cites this paper
• Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

  2018cites this paper
• Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration

  2018cites this paper
• Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure

  2018cites this paper
• β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

  2018cites this paper
• Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease

  2018cites this paper
• PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters

  2018cites this paper
• Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

  2018cites this paper
• Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics

  2018cites this paper
• Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens.

  2018cites this paper
• Drug Metabolism in Kidney Disease

  2017cites this paper
• Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions

  2017cites this paper
• Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines

  2017cites this paper
• Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine.

  2017cites this paper
• Parathyroid hormone contributes to the down‐regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF‐&kgr;B signaling pathway in secondary hyperparathyroidism

  2017influential citation
• Disposition and clinical implications of protein-bound uremic toxins.

  2017cites this paper
• Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy?

  2017cites this paper
• The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance

  2017cites this paper
• Strength of evidence for labeled dosing recommendations in renal impairment

  2017cites this paper
• A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

  2017cites this paper
• Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

  2016cites this paper
• Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function

  2016cites this paper
• A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

  2016cites this paper
• Pharmacokinetics and safety of olodaterol administered with the respimat soft Mist inhaler in subjects with impaired hepatic or renal function

  2016cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

  2016cites this paper
• A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

  2016cites this paper
• Studies of drug disposition in hemodialysis patients : impact of genetics, inflammation and vitamin D

  2016cites this paper
• Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin

  2016cites this paper
• Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999–2010

  2016influential citation
• Drug Metabolism and Chronic Kidney Disease

  2015cites this paper
• Inflammation-Induced Phenoconversion of Polymorphic Drug Metabolizing Enzymes: Hypothesis with Implications for Personalized Medicine

  2015cites this paper
• [Drug pharmacokinetics in renal failure: What's new?].

  2015cites this paper
• Pharmacocinétique des médicaments en insuffisance rénale : nouveautés

  2015cites this paper
• Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.

  2015cites this paper
• CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

  2015cites this paper
• Renal Dosing in High-Risk Populations

  2015cites this paper
• Handling of Drugs in Children with Abnormal Renal Function

  2015cites this paper
• Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

  2015cites this paper
• Excretion: Principle, Methods, and Applications for Better Therapy

  2015cites this paper
• Regulation of Hepatic Drug Metabolizing Enzymes in Chronic Kidney Disease

  2015influential citation
• The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.

  2015cites this paper
• Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients

  2014cites this paper
• Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error

  2014cites this paper
• Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15‐0444)

  2014cites this paper
• Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.

  2014cites this paper
• Kidney function assessment and its role in drug development, review and utilization

  2014influential citation
• Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients

  2014cites this paper
• Consequences of Renal Failure on Non-Renal Clearance of Drugs

  2014cites this paper
• Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug

  2014cites this paper